Background Pituitary adenoma is one of the most common brain tumors. Most pituitary
adenomas are benign and can be cured by surgery and/or medication. However, some …

Pituitary neuroendocrine tumors (PitNETs) account for approximately 15% of all intracranial
neoplasms. Although they usually appear to be benign, some tumors display worse …

Current guidelines recommend temozolomide as the first-line chemotherapy for aggressive
pituitary neuroendocrine tumours. However, no clinical trials have been conducted to date …

In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the
cornerstone. However, there are some limitations and MRI can be non-conclusive. The …

Invasion of the cavernous sinus by pituitary adenomas impedes complete surgical resection,
compromises biochemical remission, and increases the risk of further tumor recurrence …

Introduction Aggressive prolactinomas (APRLs) pose a significant clinical challenge due to
their high rate of regrowth and potentially life-threatening complications. In this study, we …

Establishing novel therapies for rare central nervous system (CNS) tumors is arduous due to
challenges in conducting clinical trials in rare tumors. Immunotherapy treatment has been a …

Simple Summary Pituitary tumours are slowly growing tumours of the pituitary gland, and
they can cause damage due to the invasion or compression of surrounding tissues, such as …

Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and
approximately one-fifth of them are diagnosed in males. The clinical presentation of …

Introduction Pituitary adenomas can show a tendency to grow, despite multimodal treatment.
Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary …